← Back to Search

Vaccine

Vaccine Dose Group 8 mcg dose for Influenza

Phase 2
Waitlist Available
Research Sponsored by VaxInnate Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through day 90
Awards & highlights

Study Summary

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent influenza vaccine. The subjects will be randomized at a 1:1:1 ratio.

Eligible Conditions
  • Influenza

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through day 90
This trial's timeline: 3 weeks for screening, Varies for treatment, and through day 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Seroconversion rates to the 4 components of VAX2012Q
Secondary outcome measures
C-reactive protein levels
Immunogenicity of the two dose levels of VAX2012Q and of Fluzone Quadrivalent
Long term safety following vaccination assessed by Clinically significant AEs
+1 more
Other outcome measures
Breadth of immunity
Duration of immunity

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Vaccine Dose Group 8 mcg doseExperimental Treatment1 Intervention
VAX2012Q, 8 mcg dose
Group II: Vaccine Dose Group 12 mcg doseExperimental Treatment1 Intervention
VAX2012Q, 12 mcg dose
Group III: ControlActive Control1 Intervention
Fluzone Quadrivalent vaccine

Find a Location

Who is running the clinical trial?

AccelovanceIndustry Sponsor
15 Previous Clinical Trials
3,593 Total Patients Enrolled
VaxInnate CorporationLead Sponsor
11 Previous Clinical Trials
1,704 Total Patients Enrolled
Department of Health and Human ServicesFED
226 Previous Clinical Trials
928,499 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years
2015. "Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02434276.
All > Influenza
~45 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top